Study of Adebrelimab with Chemoradiotherapy Followed by Surgery for Adults with Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

What this Trial Is About

Researchers are evaluating a new treatment approach for adults with locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma, a type of stomach cancer with poor survival rates. This Phase II trial aims to assess the safety and effectiveness of combining Adebrelimab, chemotherapy, and low-dose radiotherapy before surgery. The study focuses on patients with potentially resectable tumors and limited metastases, as current treatments for this group are not well-defined. Participants in the trial will receive Adebrelimab given intravenously every three weeks alongside chemotherapy drugs oxaliplatin and capecitabine following the XELOX regimen. Radiotherapy will be applied differently depending on the metastatic lesions resectability, with stereotactic body radiotherapy SBRT for unresectable lesions and low-dose radiotherapy for potentially resectable ones. Surgery to remove the tumor will be performed 3 to 5 weeks after the completion of these therapies. During the study, participants will be closely monitored for treatment safety up to 18 months after enrollment. Researchers will also assess surgical success rates, complete pathological response, progression-free survival, and overall survival over periods up to three years. Evaluations include imaging scans, lab tests, and clinical assessments to track tumor response and patient health throughout and after treatment.

Adebrelimab With Chemoradiotherapy and Surgery for G/GEJ